Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Cited by (180)

Items 101–180 of 180

1. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis
   Haigh, Laura, Kirk, Colette, El Gendy, Khalil, Gallacher, Jennifer, Errington, Linda, Mathers, John C., Anstee, Quentin M. · 2022 · Clinical Nutrition
2. Oxidative stress and antioxidants: Distress or eustress?
   Niki, Etsuo · 2016 · Archives of Biochemistry and Biophysics
3. Collagen biology and non‐invasive biomarkers of liver fibrosis
   Karsdal, Morten A., Daniels, Samuel J., Holm Nielsen, Signe, Bager, Cecilie, Rasmussen, Daniel G.K., Loomba, Rohit, Surabattula, Rambabu, Villesen, Ida Falk, Luo, Yi, Shevell, Diane et al. · 2020 · Liver International
4. Novel therapeutic targets for cholestatic and fatty liver disease
   Trauner, Michael, Fuchs, Claudia Daniela · 2022 · Gut
5. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis
   Vilar‐Gomez, Eduardo, Vuppalanchi, Raj, Gawrieh, Samer, Ghabril, Marwan, Saxena, Romil, Cummings, Oscar W., Chalasani, Naga · 2020 · Hepatology
6. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study
   Huang, Daniel Q., Wilson, Laura A., Behling, Cynthia, Kleiner, David E., Kowdley, Kris V., Dasarathy, Srinivasan, Amangurbanova, Maral, Terrault, Norah A., Diehl, Anna Mae, Chalasani, Naga et al. · 2023 · Gastroenterology
7. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
   Souza-Mello, Vanessa · 2015 · World Journal of Hepatology
8. Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis
   Patel, Niraj S., Doycheva, Iliana, Peterson, Michael R., Hooker, Jonathan, Kisselva, Tatiana, Schnabl, Bernd, Seki, Ekihiro, Sirlin, Claude B., Loomba, Rohit · 2015 · Clinical Gastroenterology and Hepatology
9. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
   Chehrehgosha, Haleh, Sohrabi, Masoud Reza, Ismail-Beigi, Faramarz, Malek, Mojtaba, Reza Babaei, Mohammad, Zamani, Farhad, Ajdarkosh, Hossein, Khoonsari, Mahmood, Fallah, Afshin Eshghi, Khamseh, Mohammad E. · 2021 · Diabetes Therapy
10. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
    Huttasch, Maximilian, Roden, Michael, Kahl, Sabine · 2024 · Metabolism
11. Pathophysiology of NASH: perspectives for a targeted treatment
    Marra, Fabio, Lotersztajn, Sophie · 2013 · Current Pharmaceutical Design
12. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
    Alkhouri, Naim, Lawitz, Eric, Noureddin, Mazen, DeFronzo, Ralph, Shulman, Gerald I. · 2020 · Expert Opinion on Investigational Drugs
13. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner
    Nishizawa, Hitoshi, Iguchi, Genzo, Fukuoka, Hidenori, Takahashi, Michiko, Suda, Kentaro, Bando, Hironori, Matsumoto, Ryusaku, Yoshida, Kenichi, Odake, Yukiko, Ogawa, Wataru et al. · 2016 · Scientific Reports
14. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials
    Brunt, Elizabeth M., Kleiner, David E., Wilson, Laura A., Sanyal, Arun J., Neuschwander‐Tetri, Brent A., for the Nonalcoholic Steatohepatitis Clinical Research Network · 2019 · Hepatology
15. Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease
    Heebøll, Sara, Kreuzfeldt, Martin, Hamilton-Dutoit, Stephen, Kjær Poulsen, Marianne, Stødkilde-Jørgensen, Hans, Møller, Holger Jon, Jessen, Niels, Thorsen, Kasper, Kristina Hellberg, Ylva, Bønløkke Pedersen, Steen et al. · 2016 · Scandinavian Journal of Gastroenterology
16. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
    Mantovani, A., Byrne, C.D., Scorletti, E., Mantzoros, C.S., Targher, G. · 2020 · Diabetes & Metabolism
17. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone
    Ohki, Takamasa, Isogawa, Akihiro, Iwamoto, Masahiko, Ohsugi, Mitsuru, Yoshida, Haruhiko, Toda, Nobuo, Tagawa, Kazumi, Omata, Masao, Koike, Kazuhiko · 2012 · The Scientific World Journal
18. Lipid metabolism in MASLD and MASH: From mechanism to the clinic
    Carli, Fabrizia, Della Pepa, Giuseppe, Sabatini, Silvia, Vidal Puig, Antonio, Gastaldelli, Amalia · 2024 · JHEP Reports
19. Breakthroughs in therapies for NASH and remaining challenges
    Ratziu, Vlad, Francque, Sven, Sanyal, Arun · 2022 · Journal of Hepatology
20. Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis
    Yu, Junjie, Zhu, Changyu, Wang, Xiaobo, Kim, KyeongJin, Bartolome, Alberto, Dongiovanni, Paola, Yates, Katherine P., Valenti, Luca, Carrer, Michele, Sadowski, Thorsten et al. · 2021 · Science Translational Medicine
21. Obeticholic acid-a new therapy in PBC and NASH
    Chapman, Roger W, Lynch, Kate D · 2020 · British Medical Bulletin
22. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
    Sathyanarayana, Padma, Jogi, Medhavi, Muthupillai, Raja, Krishnamurthy, Ramkumar, Samson, Susan L., Bajaj, Mandeep · 2011 · Obesity
23. Non-alcoholic Fatty Liver Disease (NAFLD) as a Neglected Metabolic Companion of Psychiatric Disorders: Common Pathways and Future Approaches
    Soto-Angona, Óscar, Anmella, Gerard, Valdés-Florido, María José, De Uribe-Viloria, Nieves, Carvalho, Andre F., Penninx, Brenda W. J. H., Berk, Michael · 2020 · BMC Medicine
24. EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study
    Ratziu, Vlad, Rinella, Mary E., Neuschwander-Tetri, Brent A., Lawitz, Eric, Denham, Douglas, Kayali, Zeid, Sheikh, Aasim, Kowdley, Kris V., Desta, Taddese, Elkhashab, Magdy et al. · 2022 · Journal of Hepatology
25. Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease
    Vuppalanchi, Raj, Jain, Ajay K., Deppe, Ross, Yates, Katherine, Comerford, Megan, Masuoka, Howard C., Neuschwander-Tetri, Brent A., Loomba, Rohit, Brunt, Elizabeth M., Kleiner, David E. et al. · 2014 · Clinical Gastroenterology and Hepatology
26. Understanding the cellular interactome of non-alcoholic fatty liver disease
    Wallace, Sebastian J., Tacke, Frank, Schwabe, Robert F., Henderson, Neil C. · 2022 · JHEP Reports
27. A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients With Nonalcoholic Fatty Liver Disease
    Zhang, Pei-Wen, Chen, Feng-Xia, Li, Di, Ling, Wen-Hua, Guo, Hong-Hui · 2015 · Medicine
28. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience
    Perumpail, Ryan B., Wong, Robert J., Ahmed, Aijaz, Harrison, Stephen A. · 2015 · Digestive Diseases and Sciences
29. Nonalcoholic fatty liver disease – current status and future directions
    Demir, Münevver, Lang, Sonja, Steffen, Hans‐Michael · 2015 · Journal of Digestive Diseases
30. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of 11 epidemiological studies
    Hayat, Umar, Siddiqui, Ali A., Okut, Hayrettin, Afroz, Saba, Tasleem, Syed, Haris, Ahmed · 2021 · Annals of Hepatology
31. International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation
    Tsochatzis, Emmanuel, Coilly, Audrey, Nadalin, Silvio, Levistky, Josh, Tokat, Yaman, Ghobrial, Mark, Klinck, John, Berenguer, Marina · 2019 · Transplantation
32. Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease
    Haus, Jacob M., Solomon, Thomas P.J., Kelly, Karen R., Fealy, Ciaran E., Kullman, Emily L., Scelsi, Amanda R., Lu, Lan, Pagadala, Mangesh R., McCullough, Arthur J., Flask, Chris A. et al. · 2013 · The Journal of Clinical Endocrinology & Metabolism
33. Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis
    Schon, Hans-Theo, Bartneck, Matthias, Borkham-Kamphorst, Erawan, Nattermann, Jacob, Lammers, Twan, Tacke, Frank, Weiskirchen, Ralf · 2016 · Frontiers in Pharmacology
34. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial
    Bril, Fernando, Portillo Sanchez, Paola, Lomonaco, Romina, Orsak, Beverly, Hecht, Joan, Tio, Fermin, Cusi, Kenneth · 2017 · The Journal of Clinical Endocrinology & Metabolism
35. The Multifaceted Roles of Macrophages in NAFLD Pathogenesis
    Vonderlin, Joscha, Chavakis, Triantafyllos, Sieweke, Michael, Tacke, Frank · 2023 · Cellular and Molecular Gastroenterology and Hepatology
36. Nutrition in the management of cirrhosis and its neurological complications
    Bémeur, Chantal, Butterworth, Roger F. · 2014 · Journal of Clinical and Experimental Hepatology
37. Evaluation of PXL065–deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)
    Harrison, Stephen A., Thang, Carole, Bolze, Sébastien, Dewitt, Sheila, Hallakou-Bozec, Sophie, Dubourg, Julie, Bedossa, Pierre, Cusi, Kenneth, Ratziu, Vlad, Grouin, Jean-Marie et al. · 2023 · Journal of Hepatology
38. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
    Majzoub, Abdul M., Nayfeh, Tarek, Barnard, Abbey, Munaganuru, Nagambika, Dave, Shravan, Singh, Siddharth, Murad, Mohammad Hassan, Loomba, Rohit · 2021 · Alimentary Pharmacology & Therapeutics
39. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum
    Glass, Oliver, Filozof, Claudia, Noureddin, Mazen, Berner-Hansen, Mark, Schabel, Elmer, Omokaro, Stephanie O., Schattenberg, Jörn M., Barradas, Katherine, Miller, Veronica, Francque, Sven et al. · 2020 · Journal of Hepatology
40. Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
    Ratziu, Vlad, Friedman, Scott L. · 2023 · Gastroenterology
41. Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation: A Randomized, Placebo-Controlled Clinical Trial
    Werzowa, Johannes, Hecking, Manfred, Haidinger, Michael, Lechner, Felix, Döller, Dominik, Pacini, Giovanni, Stemer, Gunar, Pleiner, Johannes, Frantal, Sophie, Säemann, Marcus D. · 2013 · Transplantation
42. Diabetes medications and risk of HCC
    Plaz Torres, Maria Corina, Jaffe, Ariel, Perry, Rachel, Marabotto, Elisa, Strazzabosco, Mario, Giannini, Edoardo G. · 2022 · Hepatology
43. Antibody-Directed Glucocorticoid Targeting to CD163 in M2-Type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes
    Svendsen, Pia, Graversen, Jonas H., Etzerodt, Anders, Hager, Henrik, Røge, Rasmus, Grønbæk, Henning, Christensen, Erik I., Møller, Holger J., Vilstrup, Hendrik, Moestrup, Søren K. · 2017 · Molecular Therapy - Methods & Clinical Development
44. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial
    Della Pepa, Giuseppe, Russo, Marco, Vitale, Marilena, Carli, Fabrizia, Vetrani, Claudia, Masulli, Maria, Riccardi, Gabriele, Vaccaro, Olga, Gastaldelli, Amalia, Rivellese, Angela A. et al. · 2021 · Diabetes Research and Clinical Practice
45. Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis
    Corey, Kathleen E., Klebanoff, Matthew J., Tramontano, Angela C., Chung, Raymond T., Hur, Chin · 2016 · Digestive Diseases and Sciences
46. An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis
    Luo, Yi, Oseini, Abdul, Gagnon, Robert, Charles, Edgar D., Sidik, Kurex, Vincent, Robert, Collen, Rebeca, Idowu, Michael, Contos, Melissa J., Mirshahi, Faridoddin et al. · 2018 · Scientific Reports
47. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
    Consoli, A., Formoso, G. · 2013 · Diabetes, Obesity and Metabolism
48. A critical review of endpoints for non-cirrhotic NASH therapeutic trials
    Ratziu, Vlad · 2018 · Journal of Hepatology
49. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity
    Guy, Cynthia D., Suzuki, Ayako, Abdelmalek, Manal F., Burchette, James L., Diehl, Anna Mae, for the NASH CRN · 2015 · Hepatology
50. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Dong, Yajie, Lv, Qingguo, Li, Sheyu, Wu, Yuan, Li, Ling, Li, Juan, Zhang, Fang, Sun, Xin, Tong, Nanwei · 2017 · Clinics and Research in Hepatology and Gastroenterology
51. The immune landscape in nonalcoholic steatohepatitis
    Narayanan, Sowmya, Surette, Fionna A., Hahn, Young S. · 2016 · Immune Network
52. Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
    Svegliati-Baroni, Gianluca, Patrício, Bárbara, Lioci, Gessica, Macedo, Maria Paula, Gastaldelli, Amalia · 2020 · International Journal of Molecular Sciences
53. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score
    Tapper, Elliot B., Hunink, M. G. Myriam, Afdhal, Nezam H., Lai, Michelle, Sengupta, Neil · 2016 · PLoS ONE
54. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis
    Panunzi, Simona, Maltese, Sabina, Verrastro, Ornella, Labbate, Luca, De Gaetano, Andrea, Pompili, Maurizio, Capristo, Esmeralda, Bornstein, Stefan R., Mingrone, Geltrude · 2021 · Diabetes, Obesity and Metabolism
55. Novel metabolites and roles for α-tocopherol in humans and mice discovered by mass spectrometry–based metabolomics
    Johnson, Caroline H, Slanař, Ondřej, Krausz, Kristopher W, Kang, Dong Wook, Patterson, Andrew D, Kim, Jung-Hwan, Luecke, Hans, Gonzalez, Frank J, Idle, Jeffrey R · 2012 · The American Journal of Clinical Nutrition
56. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin
    Gonciarz, Maciej, Bielański, Wladyslaw, Partyka, Robert, Brzozowski, Tomasz, Konturek, Piotr C., Eszyk, Jerzy, Celiński, Krzysztof, Reiter, Russel J., Konturek, Stanislaw J. · 2013 · Journal of Pineal Research
57. Management of metabolic-associated fatty liver disease: The diabetology perspective
    Jeeyavudeen, Mohammad Sadiq, Khan, Shahanas KA, Fouda, Sherouk, Pappachan, Joseph M · 2023 · World Journal of Gastroenterology
58. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
    Bril, Fernando, Barb, Diana, Lomonaco, Romina, Lai, Jinping, Cusi, Kenneth · 2020 · Journal of Hepatology
59. Metabolic syndrome and its association with nonalcoholic steatohepatitis
    Bril, Fernando, Sanyal, Arun, Cusi, Kenneth · 2023 · Clinics in Liver Disease
60. Impact of Time-Restricted Feeding and Dawn-to-Sunset Fasting on Circadian Rhythm, Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
    Mindikoglu, Ayse L., Opekun, Antone R., Gagan, Sood K., Devaraj, Sridevi · 2017 · Gastroenterology Research and Practice
61. SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology
    Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki et al. · 2020 · Internal Medicine
62. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
    Mazzotti, Arianna, Caletti, Maria Turchese, Marchignoli, Francesca, Forlani, Giulia, Marchesini, Giulio · 2017 · Digestive and Liver Disease
63. Insulin Signaling as a Potential Natural Killer Cell Checkpoint in Fatty Liver Disease
    Amer, Johnny, Salhab, Ahmad, Noureddin, Mazen, Doron, Sarit, Abu‐Tair, Lina, Ghantous, Rami, Mahamid, Mahmud, Safadi, Rifaat · 2018 · Hepatology Communications
64. Treatment Candidacy for Pharmacologic Therapies for NASH
    Rowe, Ian A., Wong, Vincent Wai-Sun, Loomba, Rohit · 2022 · Clinical Gastroenterology and Hepatology
65. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials
    Gu, Yunpeng, Sun, Lei, He, Yining, Yang, Luping, Deng, Chaohua, Zhou, Run, Kong, Tingting, Zhang, Wei, Chen, Yutong, Li, Jie et al. · 2023 · Expert Review of Gastroenterology & Hepatology
66. Pharmacological treatment of MASLD: contemporary treatment and future perspectives
    Drygalski, Krzysztof · 2025 · International Journal of Molecular Sciences
67. Managing diabetes in patients with chronic liver disease
    Khan, Roaid, Foster, Graham R., Chowdhury, Tahseen A. · 2012 · Postgraduate Medicine
68. Dietary vitamin E intake is associated with a reduced risk of developing digestive diseases and nonalcoholic fatty liver disease
    Scorletti, Eleonora, Creasy, Kate Townsend, Vujkovic, Marijana, Vell, Mara, Zandvakili, Inuk, Rader, Daniel J., Schneider, Kai Markus, Schneider, Carolin V. · 2022 · American Journal of Gastroenterology
69. Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)–April 2022–AWMF Registration No.: 021–025
    Authors, Collaborators: · 2022 · Zeitschrift für Gastroenterologie
70. Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
    Sen, Partho, Govaere, Olivier, Sinioja, Tim, McGlinchey, Aidan, Geng, Dawei, Ratziu, Vlad, Bugianesi, Elisabetta, Schattenberg, Jörn M., Vidal-Puig, Antonio, Allison, Michael et al. · 2022 · iScience
71. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery
    Russo, Maria Francesca, Lembo, Erminia, Mari, Andrea, Angelini, Giulia, Verrastro, Ornella, Nanni, Giuseppe, Pompili, Maurizio, Raffaelli, Marco, Vecchio, Fabio Maria, Bornstein, Stefan R et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
72. Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms
    Heinle, James Westley, DiJoseph, Kara, Sabag, Angelo, Oh, Sechang, Kimball, Scot R., Keating, Shelley, Stine, Jonathan G. · 2023 · Nutrients
73. The association of nonalcoholic steatohepatitis and obstructive sleep apnea
    Asfari, Mohammad M., Niyazi, Fadi, Lopez, Rocio, Dasarathy, Srinivasan, McCullough, Arthur J. · 2017 · European Journal of Gastroenterology & Hepatology
74. Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes
    Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., Cuthbertson, D. J. · 2020 · Diabetic Medicine
75. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH
    Stine, Jonathan G., Schreibman, Ian, Navabi, Seyedehsan, Kang, Mitchell, Dahmus, Jessica, Soriano, Christopher, Rivas, Gloriany, Hummer, Breianna, Beyer, Megan, Tressler, Heather et al. · 2020 · Contemporary Clinical Trials Communications
76. Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis
    Bharaj, Inderjeet Singh, Brar, Ajit Singh, Kahlon, Jasraj, Singh, Anmol, Hotwani, Priya, Kumar, Vikash, Sohal, Aalam, Batta, Akash · 2025 · World Journal of Cardiology
77. Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3
    St. Rose, Kristy, Yan, Jun, Xu, Fangxi, Williams, Jasmine, Dweck, Virginia, Saxena, Deepak, Schwabe, Robert F., Caviglia, Jorge Matias · 2022 · Hepatology Communications
78. Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver
    Hunter, Harriet, de Gracia Hahn, Dana, Duret, Amedine, Im, Yu Ri, Cheah, Qinrong, Dong, Jiawen, Fairey, Madison, Hjalmarsson, Clarissa, Li, Alice, Lim, Hong Kai et al. · 2020 · eLife
79. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring
    Shamseddeen, Hani, Vilar-Gomez, Eduardo, Chalasani, Naga, Myers, Robert P., Subramanian, G. Mani, Shlevin, Harold H., Allgood, Adam E., Orman, Eric S. · 2020 · Drug Safety
80. Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
    Brennan, Paul N, The University of Edinburgh, Centre for Regenerative Medicine, Edinburgh, UK, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK, The University of Dundee, Department of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK, Dillon, John F, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK, The University of Dundee, Department of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK, McCrimmon, Rory, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK, The University of Dundee, Department of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK · 2022 · European Endocrinology